Mavacamten Use Can Reduce Need for Septal Reduction Therapy

Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.

Related Keywords

Roberto Bonow , Jamese Udelson , Amy Sehnert , Milind Desai , Vascular Thoracic Institute At Cleveland Clinic , Bristol Myers Squibb , American College Of Cardiology Heart Association , European Society Of Cardiology , European Society , Thoracic Institute , American Heart Association , Confidence Interval , Heart Failure Clinical Development , Bristol Myers , Mitigation Strategy , Septal Reduction , Term Efficacy , Esc Congress 2023 , Cardiology , Hypertrophic Cardiomyopathy , Johcm , Mavacamten , Camzyos ,